A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Constitutive activation of key cellular regulators drives cancer cell growth and is a target for cancer therapy.
• The BRAF V600E mutation promotes cancer cell growth and survival, and is prevalent in various cancers, including lung cancer.
• Targeted therapies like dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) have improved outcomes for advanced NSCLC patients with BRAF V600E/K mutations.

Purpose of the Study:

• To establish a highly sensitive and specific real-time quantitative PCR (RT-qPCR) method for detecting BRAF V600E/K mutations in lung cancer.
• To investigate the incidence and clinicopathological features of BRAF V600E/K mutations in lung cancer patients from southern Taiwan.
• To compare the diagnostic performance of the established RT-qPCR method with BRAF V600E-specific immunohistochemistry.

Main Methods:

• Development and validation of a sensitive real-time quantitative PCR (RT-qPCR) assay capable of detecting single-digit copies of mutant DNA.
• Comparison of RT-qPCR with BRAF V600E-specific immunohistochemistry for mutation detection in a cohort of lung cancer patients.
• Analysis of mutation frequency and correlation with clinicopathological features in the studied patient population.

Main Results:

• The BRAF V600E mutation was found at a low frequency of 0.65% (2/306) in the southern Taiwan lung cancer patient cohort.
• The developed RT-qPCR method and BRAF V600E-specific immunohistochemistry demonstrated high diagnostic accuracy, with sensitivity and specificity reaching 100% and 97.6%, respectively.
• Simultaneous screening using both RT-qPCR and immunohistochemistry can enhance the accuracy of BRAF V600E/K mutation detection.

Conclusions:

• A highly sensitive RT-qPCR method for BRAF V600E/K mutation detection has been successfully established and validated.
• The study provides data on the low incidence of BRAF V600E mutations in lung cancer patients in southern Taiwan.
• Combined application of RT-qPCR and immunohistochemistry improves the accuracy of diagnosing BRAF V600E/K mutations, crucial for guiding targeted therapy.